

RECEIVED  
CENTRAL FAX CENTER

APR 26 2004

Attorney's Docket 037003-0275463  
Client Reference: 1992-30-0029CP2

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

OFFICIAL

In re PATENT APPLICATION of:  
DARRELL R ANDERSON ET AL.

Confirmation No: 9119

Application No.: 08/921,060

Group Art Unit: 1844

Filed: August 29, 1997

Examiner: Ronald B. Schwadron

Title: THERAPEUTIC APPLICATION OF CHIMERIC AND RADIOLABELED  
ANTIBODIES TO HUMAN B LYMPHOCYTE RESTRICTED DIFFERENTIATION  
ANTIGEN FOR TREATMENT OF B CELL LYMPHOMA


Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

CERTIFICATION OF FACSIMILE TRANSMISSION  
UNDER 37 C.F.R. §1.8

I hereby certify that the following papers are being facsimile  
transmitted to the Patent and Trademark Office at (703) 872-9306 on the date  
shown below:

Election Response (1 page)

PILLSBURY WINTHROP LLP



THOMAS A. CAWLEY, JR., PH.D.  
Reg. No. 40944

Date: April 26, 2004  
P.O. Box 10500  
McLean, VA 22102  
Telephone: (703) 905-2000  
Facsimile: (703) 905-2500

(Certification of Facsimile Transmission--page 1)

U.S. Appl. No. 08/921,060  
Attorney Docket No. 037003-0275463

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re PATENT APPLICATION OF

ANDERSON et al.

Group Art Unit: 1644

Application No. 08/921,060

Examiner: Ronald B. Schwadron

Filed: August 29, 1997

Title: THERAPEUTIC APPLICATION OF CHIMERIC AND RADIOLABELED  
ANTIBODIES TO HUMAN B LYMPHOCYTE RESTRICTED DIFFERENTIATION  
ANTIGEN FOR TREATMENT OF B CELL LYMPHOMA

\* \* \* \* \*

**ELECTION RESPONSE**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

This is in response to the official communication mailed on March 24, 2004. Applicants elect, with traverse, the method of claim 44, which is directed to methods for depletion of B cells by administration of an antibody having the complementarity determining regions (CDRs) of the 2B8 antibody. Traversal is on the grounds that the antibody specified in claim 43, *i.e.*, an antibody having the heavy chain variable region and the light chain variable region are within the scope of the antibodies specified in claim 44. Therefore, the examiner will not have to undertake any additional search efforts to examine both the methods of claim 43 and 44. On this basis, rejoinder of claims 43 and 44 is respectfully requested.

If there are any remaining questions regarding the election of species, applicants respectfully request that the examiner contact the undersigned attorney.

Respectfully submitted,

PILLSBURY WINTHROP LLP



Thomas A. Cawley, Jr., Ph.D.  
Registration No. 40,944

April 26, 2004  
P.O. Box 10500  
McLean, VA 22102  
(703) 905-2144 Direct Dial  
(703) 905-2500 Facsimile  
TAC/JBM

30450451v1

-1-